Market News AIOpen the app

Pomerantz LLP is looking into Krystal Biotech, Inc. for possible fraud after delays caused its stock price to drop.

RulesRead the original at globenewswire.com
Bad for KRYS

Krystal Biotech's data releases for several product candidates moved from expected 2026 timing to 2027, delaying evidence of their promise. A law firm is investigating possible wrongdoing, but has not established it; the delay is the clearer concern.

KRYS · Krystal Biotech, Inc.

AI read · Bad for KRYS

The AI's read

Investors now have to wait longer to learn whether several candidates show promise. The law firm's inquiry raises a concern, but it has not established wrongdoing. The delay is the clearer reason for concern.

Get alerts for KRYS

Follow Krystal Biotech, Inc. (KRYS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for KRYS
Free on the App Store and Google Play, or on the web.